In addition to its antipsychotic properties, the more extensive. More evidence of the protective effects of CBD against the psychotomimetic, anxiogenic and cognition-damaging effects of THC comes from experimental studies in which the two cannabinoids have been administered together. THC can be used as an experimental model of psychosis in humans because its acute administration in healthy people can cause transient psychotic symptoms (including positive and negative symptoms), as well as cognitive deficits similar to those observed in schizophrenia. 41—47 In one study, six healthy volunteers received THC intravenously (1.25 mg) twice, one preceded by an intravenous placebo and another with CBD (2.5 mg) in a double-blind subject design, 24 At the group level, the administration of THC with pretreatment with pretreatment with Placebo was associated with transient psychotomimetic effects, which were not observed under conditions prior to treatment with CBD, 24 A larger study between groups (n %3D 4) showed that, compared to placebo, pretreatment with 600 mg of oral CBD reduced paranoia and alterations in episodic memory caused by 1.5 mg of intravenous THC, 23. Unlike Δ9-THC, cannabidiol seems to have no psychotomimetic potential, but it shows antipsychotic effects in humans and humans.
Therefore, this review focuses on (preclinical studies investigating cannabidiol as a possible antipsychotic in animal models of aspects of schizophrenia), (clinical evidence of its antipsychotic action) and (the possible mechanisms of action and their possible relevance to the antipsychotic effects of cannabidiol). Medical cannabis has received greater research attention in recent years due to the easing of global regulatory changes. Medical cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, nausea and vomiting induced by chemotherapy, and intractable childhood epilepsy. However, its possible application in the field of psychiatry is less well known.
If there is a personal or family history of psychosis and, if so, the use of THC is not recommended; The initial observation that CBD reduced psychotic symptoms induced by THC led us to carry out a pioneering study to test the effects of CBD in a model commonly used to identify drugs with an antipsychotic profile in laboratory animals.9 Stereotypy induced in rats by a dopaminergic agonist was clearly reduced with CBD, without producing the catalepsy associated with the extrapyramidal adverse effects (EA) of classic antipsychotics. This finding suggests that CBD has an atypical antipsychotic pattern. A series of other tests with different animal models confirmed and expanded the antipsychotic profile of CBD. As the cannabis plant matures, CBGA will be exposed to three different enzymes, each of which converts the compound into THCA, CBDA, or CBCA.
We test for CBDVA, CBDV, CBDA, CBGA, CBG, CBD, THCV, THCVA, CBN, Δ9THC, Δ8THC, CBL, CBC, THCA and CBCA.